WO2008114505A1 - Eg5 inhibitor and agent for treatment of cell proliferative disease containing the same - Google Patents

Eg5 inhibitor and agent for treatment of cell proliferative disease containing the same Download PDF

Info

Publication number
WO2008114505A1
WO2008114505A1 PCT/JP2008/000617 JP2008000617W WO2008114505A1 WO 2008114505 A1 WO2008114505 A1 WO 2008114505A1 JP 2008000617 W JP2008000617 W JP 2008000617W WO 2008114505 A1 WO2008114505 A1 WO 2008114505A1
Authority
WO
WIPO (PCT)
Prior art keywords
group
agent
treatment
cell proliferative
inhibitor
Prior art date
Application number
PCT/JP2008/000617
Other languages
French (fr)
Japanese (ja)
Inventor
Akira Asai
Junichi Sawada
Kenji Matsuno
Naohisa Ogo
Nobutaka Fujii
Shinya Oishi
Original Assignee
Pharma Ip Limited Liability Intermediary Corporations
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Ip Limited Liability Intermediary Corporations filed Critical Pharma Ip Limited Liability Intermediary Corporations
Priority to JP2009505077A priority Critical patent/JPWO2008114505A1/en
Publication of WO2008114505A1 publication Critical patent/WO2008114505A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Disclosed is an Eg5 inhibitor containing a cysteine derivative represented by the formula (I) below or a pharmacologically acceptable salt thereof as an active ingredient. Also disclosed is an agent for treatment of cell proliferative diseases. [chemical formula 1] (I) (In the formula, Ar represents a substituted or unsubstituted aryl group or a substituted or unsubstituted aromatic heterocyclic group; R1 represents a hydrogen atom or a protecting group of an amino group; and R2 represents a hydroxy group, an alkoxy group, an amino group, a -NH(CH2)2O(CH2)2NH2 group or the like. In this connection, when Ar is a phenyl group, R2 is a group other than a hydroxy group.)
PCT/JP2008/000617 2007-03-16 2008-03-17 Eg5 inhibitor and agent for treatment of cell proliferative disease containing the same WO2008114505A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2009505077A JPWO2008114505A1 (en) 2007-03-16 2008-03-17 Eg5 inhibitor and therapeutic agent for cell proliferative disease comprising the compound

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2007069487 2007-03-16
JP2007-069487 2007-03-16

Publications (1)

Publication Number Publication Date
WO2008114505A1 true WO2008114505A1 (en) 2008-09-25

Family

ID=39765623

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2008/000617 WO2008114505A1 (en) 2007-03-16 2008-03-17 Eg5 inhibitor and agent for treatment of cell proliferative disease containing the same

Country Status (2)

Country Link
JP (1) JPWO2008114505A1 (en)
WO (1) WO2008114505A1 (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
CN103740648A (en) * 2013-11-20 2014-04-23 成都正能生物技术有限责任公司 Kinesin spindle protein (Eg5) monoclonal antibody and hybridoma cell strain secreting it
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US9902690B2 (en) 2013-12-27 2018-02-27 Novus International, Inc. Ethoxylated surfactants
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104011A2 (en) * 2006-03-08 2007-09-13 University Of Maryland, Baltimore Inhibition of microtubule protrusion in cancer cells

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007104011A2 (en) * 2006-03-08 2007-09-13 University Of Maryland, Baltimore Inhibition of microtubule protrusion in cancer cells

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DEBONIS S. ET AL.: "STRUCTURE-ACTIVITY RELATIONSHIP OF S-TRITYL-L-CYSTEINE ANALOGUES AS INHIBITORS OF THE HUMAN MITOTIC KINESIN EG5", J. MED. CHEM., vol. 51, no. 5, 13 March 2008 (2008-03-13), pages 1115 - 1125 *
KESSEL D. ET AL.: "EFFECTS OF S-(TRITYL)-L-CYSTEINE AND ITS ANALOGS ON CELL SURFACE PROPERTIES OF LEUKEMIA L1210 CELLS", BIOCHEM. PHARMACOL., vol. 25, no. 16, 1976, pages 1893 - 1897, XP023729552, DOI: doi:10.1016/0006-2952(76)90195-7 *
OGO N. ET AL.: "SYNTHESIS AND BIOLOGICAL EVALUATION OF L-CYSTEINE DERIVATIVES AS MITOTIC KINESIN EG5 INHIBITORS", BIOORG. MED. CHEM. LETT., vol. 17, no. 14, 15 July 2007 (2007-07-15), pages 3921 - 3924, XP022119981 *
ZEE-CHENG K.Y. ET AL.: "EXPERIMENTAL ANTILEUKEMIC AGENTS. PREPARATION AND STRUCTURE-ACTIVITY STUDY OF S-TRITYLCYSTEINE AND RELATED COMPOUNDS", J. MED. CHEM., vol. 13, no. 3, 1970, pages 414 - 418, XP002919020 *
ZEE-CHENG K.Y. ET AL.: "STRUCTURAL MODIFICATION OF S-TRITYL-L-CYSTEINE. PREPARATION OF SOME S-(SUBSTITUTED TRITYL)-L-CYSTEINES AND DIPEPTIDES OF TRITYL-L-CYSTEINE", J. MED. CHEM., vol. 15, no. 1, 1972, pages 13 - 16, XP002398931 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8349899B1 (en) 2008-12-03 2013-01-08 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
US8765817B1 (en) 2008-12-03 2014-07-01 Arrowhead Center, Inc. Selective inhibitors of EG5 motors and methods of use
CN103740648A (en) * 2013-11-20 2014-04-23 成都正能生物技术有限责任公司 Kinesin spindle protein (Eg5) monoclonal antibody and hybridoma cell strain secreting it
CN103740648B (en) * 2013-11-20 2016-08-31 成都汇瑞新元生物科技有限责任公司 A kind of spindle kinesin (Eg5) monoclonal antibody and secrete the hybridoma cell strain of this monoclonal antibody
US9902690B2 (en) 2013-12-27 2018-02-27 Novus International, Inc. Ethoxylated surfactants
US10584306B2 (en) 2017-08-11 2020-03-10 Board Of Regents Of The University Of Oklahoma Surfactant microemulsions

Also Published As

Publication number Publication date
JPWO2008114505A1 (en) 2010-07-01

Similar Documents

Publication Publication Date Title
EP1921077A4 (en) Agent for treating and/or preventing sleep disorder
WO2008114812A1 (en) Jak inhibitor
WO2008111441A1 (en) Pharmaceutical composition
WO2008126901A1 (en) Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
WO2008087933A1 (en) NOVEL INDOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON IϰB KINASE β
WO2005095395A3 (en) Tetrahydronaphthyridine derivatives as cholesteryl ester transfer protein inhibitors
WO2009069736A1 (en) Nitrogenated compound
TW200616994A (en) Novel thiophene derivatives
WO2005097129A3 (en) 6-azaindole compound
MY146532A (en) Thiazole derivative
GB2442148A (en) FK 228 derivates as HDAC inhibitors
AU2009258496A8 (en) Sulfur-containing heterocyclic derivative having beta-secretase-inhibiting activity
GEP20094605B (en) Pyrazole derivatives, compositions containing such compounds and methods of use thereof
WO2007082808A3 (en) Thiazoles as 11 beta-hsd1 inhibitors
WO2008108386A1 (en) Pharmaceutical composition
WO2007095174A3 (en) Bile acid derivatives as fxr ligands for the prevention or treatment of fxr-mediated diseases or conditions
WO2007122634A3 (en) Pyrimidinediones as tyrosine kinase inhibitors
MX2007010532A (en) 1- sulfonyl-pi perdine- 3 -carboxyl i c acid amide derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase for the treatment of type ii diabetes mellitus.
MX2009005691A (en) Inhibitors of diacylglycerol o-acylotransferase type 1 enzyme.
WO2007020213A3 (en) Thiazolyl piperidine derivatives useful as h3 receptor modulators
WO2008108378A3 (en) Bicyclic oxomorpholine derivative
EP1867331A4 (en) Triazole derivative and the use thereof
GEP20104875B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
EP1854789A4 (en) Quinazoline derivative having tyrosine kinase inhibitory activity
MX2010001566A (en) Aminopyrazole amide derivative.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08720502

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2009505077

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08720502

Country of ref document: EP

Kind code of ref document: A1